RT Journal Article
SR Electronic
T1 A FinnGen pilot clinical recall study for Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.06.23285534
DO 10.1101/2023.02.06.23285534
A1 Julkunen, Valtteri
A1 Schwarz, Claudia
A1 Kalapudas, Juho
A1 Hallikainen, Merja
A1 Piironen, Aino-Kaisa
A1 Mannermaa, Arto
A1 Kujala, Hanna
A1 Laitinen, Timo
A1 Kosma, Veli-Matti
A1 Paajanen, Teemu I.
A1 Kälviäinen, Reetta
A1 Hiltunen, Mikko
A1 Herukka, Sanna-Kaisa
A1 Kärkkäinen, Sari
A1 Kokkola, Tarja
A1 Urjansson, Mia
A1 Gen, Finn
A1 Perola, Markus
A1 Palotie, Aarno
A1 Vuoksimaa, Eero
A1 Runz, Heiko
YR 2023
UL http://medrxiv.org/content/early/2023/02/08/2023.02.06.23285534.abstract
AB Background Successful development of novel therapies requires that clinical trials are conducted in patient cohorts with the highest benefit-to-risk ratio. Population-based biobanks with comprehensive health and genetic data from large numbers of individuals hold promise to facilitate identification of trial participants, particularly when interventions need to start while symptoms are still mild, such as for Alzheimer’s disease (AD). However, few studies have yet tested whether recalling biobank participants into clinical follow-up studies is feasible.Objective To establish a process for clinical recall studies from FinnGen and demonstrate the feasibility to systematically ascertain customized clinical data from FinnGen participants with ICD10 diagnosis of AD or mild cognitive disorder (MCD).Methods Single-center cross-sectional study testing blood-based biomarkers and cognitive functioning in-person, computer-based and remote.Results 19% (27/140) of a pre-specified FinnGen subcohort were successfully recalled and completed the study. Hospital records largely validated registry entries. For 8/12 MCD patients, other reasons than AD were identified as underlying diagnosis. Cognitive measures correlated across platforms, with highest consistencies for dementia screening (r=0.818) and semantic fluency (r=0.764), respectively, for in-person versus telephone-administered tests. GFAP (p<0.002) and pTau-181 (p<0.020) most reliably differentiated AD from MCD participants.Conclusions Informative, customized clinical recall studies from FinnGen are feasible.Competing Interest StatementH.R. is a full-time employee of Biogen. A.P. is a member of the Pfizer Genetics Scientific Advisory Panel.Funding StatementThis study was funded by the FinnGen project. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie, AstraZeneca UK, Biogen, Bristol Myers Squibb (and Celgene Corporation & Celgene International II), Genentech, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Pfizer, GlaxoSmithKline Intellectual Property Development, Sanofi US Services, Maze Therapeutics, Janssen Biotech, Novartis, and Boehringer Ingelheim. Further funding to EV came from the Academy of Finland grants 314639 and 320109.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of HUS gave ethical approval for this work. Additionally, research permission was granted by from the Biobank of Eastern Finland and Kuopio University Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available in FinnGen sandbox, a safe controlled environment accessible by authorized researchers in FinnGen research community.